[go: up one dir, main page]

ATE521365T1 - Kinin-antagonisten zur behandlung von blasenfunktionsstörung - Google Patents

Kinin-antagonisten zur behandlung von blasenfunktionsstörung

Info

Publication number
ATE521365T1
ATE521365T1 AT06754662T AT06754662T ATE521365T1 AT E521365 T1 ATE521365 T1 AT E521365T1 AT 06754662 T AT06754662 T AT 06754662T AT 06754662 T AT06754662 T AT 06754662T AT E521365 T1 ATE521365 T1 AT E521365T1
Authority
AT
Austria
Prior art keywords
treatment
bladder disorder
kinin antagonists
kinin
antagonists
Prior art date
Application number
AT06754662T
Other languages
English (en)
Inventor
Christoph Gibson
Gerd Hummel
Jochen Knolle
Ulrich Reineke
Thomas Tradler
Original Assignee
Jerini Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jerini Ag filed Critical Jerini Ag
Application granted granted Critical
Publication of ATE521365T1 publication Critical patent/ATE521365T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT06754662T 2005-07-05 2006-07-04 Kinin-antagonisten zur behandlung von blasenfunktionsstörung ATE521365T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05014581A EP1741444A1 (de) 2005-07-05 2005-07-05 Antagonisten von Kinin zur Behandlung von Blasenfunktionsstoerungen
PCT/EP2006/006504 WO2007003411A2 (en) 2005-07-05 2006-07-04 Kinin antagonists for treating bladder dysfunction

Publications (1)

Publication Number Publication Date
ATE521365T1 true ATE521365T1 (de) 2011-09-15

Family

ID=34937780

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06754662T ATE521365T1 (de) 2005-07-05 2006-07-04 Kinin-antagonisten zur behandlung von blasenfunktionsstörung

Country Status (17)

Country Link
US (1) US20080221039A1 (de)
EP (2) EP1741444A1 (de)
JP (1) JP2009500362A (de)
KR (1) KR20080025120A (de)
CN (1) CN101212985A (de)
AR (1) AR054820A1 (de)
AT (1) ATE521365T1 (de)
AU (1) AU2006265266A1 (de)
BR (1) BRPI0613724A2 (de)
CA (1) CA2613627A1 (de)
IL (1) IL188316A0 (de)
RU (1) RU2008104134A (de)
SG (1) SG163564A1 (de)
TW (1) TW200800249A (de)
UA (1) UA96573C2 (de)
WO (1) WO2007003411A2 (de)
ZA (1) ZA200711240B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20041963A1 (it) * 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
DE102005013967A1 (de) * 2004-11-05 2006-10-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
FR2919803B1 (fr) * 2007-08-07 2011-07-22 Sanofi Aventis Utilisation d'un antagoniste non peptidique du recepteur b1 pour la preparation de medicaments utiles pour le traitement de l'obesite et des pathologies liees a l'obesite ou au diabete
CA2712582A1 (en) * 2008-02-06 2009-08-13 Norbert Hauel Aryl sulfonamides as effective analgesics
IT1391236B1 (it) 2008-07-11 2011-12-01 St Luso Farm D'italia Spa Composizioni farmaceutiche a base di antagonisti del recettore b2 delle chinine e corticosteroidi e loro uso
US20130323288A1 (en) 2010-07-08 2013-12-05 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
US9415048B2 (en) 2010-07-08 2016-08-16 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
SG11201500410XA (en) 2012-01-04 2015-04-29 Wellesley Pharmaceuticals Llc Delayed-release formulation for reducing the frequency of urination and method of use thereof
US10278925B2 (en) 2012-01-04 2019-05-07 Wellesley Pharmaceuticals, Llc Delayed-release formulations, methods of making and use thereof
CA2875818A1 (en) * 2012-07-27 2014-01-30 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
US10792326B2 (en) 2013-06-28 2020-10-06 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
EP3027199B1 (de) 2013-08-01 2019-06-26 Dignify Therapeutics, LLC Zusammensetzungen und verfahren zur induktion von wasserlassen und stuhlgang
CN103588861B (zh) * 2013-10-25 2015-11-04 中国药科大学 新德里金属β-内酰胺酶的抑制肽及其应用
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
BR112020010298A2 (pt) 2017-11-24 2020-11-17 Pharvaris Netherlands B.V. antagonistas de receptor b2 de bradicinina inovadores
UY38706A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
AR118983A1 (es) 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9505491D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
HRP20030027A2 (en) * 2000-06-28 2004-02-29 Teva Pharma Carvedilol
FR2822827B1 (fr) * 2001-03-28 2003-05-16 Sanofi Synthelabo Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
US7063860B2 (en) * 2001-08-13 2006-06-20 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
CA2473778A1 (en) * 2002-02-08 2003-08-14 Merck & Co., Inc. N-biphenylmethyl aminocycloalkanecarboxamide derivatives
US20040044041A1 (en) * 2002-08-06 2004-03-04 Kuduk Scott D. 2-(Biarylalkyl)amino-3-(cyanoalkanoylamino)pyridine derivatives
JP2006515327A (ja) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド ナトリウムチャネル調節因子を用いた下部尿路障害を処置するための方法
EP1590458B1 (de) * 2003-02-06 2012-10-31 Queen's University Of Belfast Ein auf den bradykinin b2-rezeptor antagonistisch wirkendes peptid aus amphibienhaut
EP1721607A1 (de) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Verfahren zur Behandlung von Erkrankungen der unteren Harnwege mittels Modulatoren der glatten Muskulatur und Modulatoren der alpha-2-delta Untereinheit des Kalziumkanals

Also Published As

Publication number Publication date
EP1741444A1 (de) 2007-01-10
CA2613627A1 (en) 2007-01-11
AR054820A1 (es) 2007-07-18
KR20080025120A (ko) 2008-03-19
SG163564A1 (en) 2010-08-30
JP2009500362A (ja) 2009-01-08
WO2007003411A3 (en) 2007-05-18
IL188316A0 (en) 2008-04-13
CN101212985A (zh) 2008-07-02
BRPI0613724A2 (pt) 2011-02-08
TW200800249A (en) 2008-01-01
EP1901775A2 (de) 2008-03-26
ZA200711240B (en) 2008-08-27
US20080221039A1 (en) 2008-09-11
WO2007003411A2 (en) 2007-01-11
AU2006265266A1 (en) 2007-01-11
EP1901775B1 (de) 2011-08-24
RU2008104134A (ru) 2009-08-10
UA96573C2 (ru) 2011-11-25

Similar Documents

Publication Publication Date Title
ATE521365T1 (de) Kinin-antagonisten zur behandlung von blasenfunktionsstörung
EP1981526A4 (de) Adiponectin zur behandlung verschiedener erkrankungen
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
DE602005020209D1 (de) System zur Evaluierung von Herzstörungen
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
DE602005015234D1 (de) Zusammensetzungen zur wäschebehandlung
DE602005014252D1 (de) Zusammensetzungen zur wäschebehandlung
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE602005019899D1 (de) System zur behandlung von ischämischem schlaganfall
EP4091585C0 (de) Vorrichtung zur behandlung von refluxösophagitis
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
EP1755661A4 (de) Verwendung von gelsolin zur behandlung von infektionen
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
DE602005015577D1 (de) Harnstoff-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
EP2249765A4 (de) Dapson zur behandlung von rosascea
DE602006010449D1 (de) Behandlung von geflügel zwecks reduzierung der futon ascites
EP1832861A4 (de) Komponente zur voranalytischen behandlung
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
ATE483460T1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties